ASH 2022 | The safety and efficacy of revumenib in patients with KMT2A-rearranged or NPM1-mutated AML
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares some insights into the AUGMENT-101 study (NCT04065399), which is evaluating the safety and efficacy of the menin inhibitor revumenib in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with KMT2A rearrangement or NPM1 mutation. Results so far have been encouraging, and Dr Stein further highlights the value of menin inhibitors as a treatment option for patients with AML. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Astellas Pharmaceutical, Agios Pharmaceuticals, and Genentech: Consultancy, Membership on an entity’s Board of Directors or advisory committees; PTC Therapeutics and Syros: Membership on an entity’s Board of Directors or advisory committees; Syndax: Consultancy, Research Funding; Amgen, AbbVie, Seattle Genetics, and Biotheryx: Consultancy; Daiichi-Sankyo, Celgene Pharmaceuticals, and Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Auron Therapeutics: Current equity holder in private company; PinotBio, Bristol Myers Squibb, Jazz Pharmaceuticals, Foghorn Therapeutics, Blueprint Medicines, Gilead Sciences, Janssen Pharmaceuticals: Consultancy; Bayer: Research Funding.
